Exelixis licenses small molecule from Insilico for $80M upfront; Vertex buys GPCR from Septerna

Exelixis is buying into a cancer drug candidate discovered by generative AI from Insilico Medicine, the two companies announced Tuesday.

The Bay Area cancer company is paying Insilico $80 million upfront for ISM3091 — a small molecule that inhibits USP1. The enzyme is an important mediator…
Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks